SCHEMBL662935

SCHEMBL662935

CCC(O)c1ccc(OC)c(OC(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
PPARG P37231 1/20 0.49
PPARD Q03181 1/20 0.49
PPARA Q07869 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
KMT2A Q03164 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NFKB1 P19838 2/20 0.47
SLC22A3 O75751 1/20 0.47
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
HIF1A Q16665 2/20 0.46
EPAS1 Q99814 2/20 0.46
PDE4D Q08499 3/20 0.45
PDE4B Q07343 3/20 0.45
PDE4A P27815 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6055371 0.88 PPARG (0.61) CYP3A4TSHRPPARGPPARDPPARA
SCHEMBL661734 0.84 CYP1A2 (0.51) CYP3A4TSHRPPARGPPARDPPARA
SCHEMBL18652088 0.81 ALDH1A1 (0.50) CYP3A4TSHRPPARGPPARDPPARA
SCHEMBL10101848 0.81 ACHE (0.43) CYP3A4TSHRNFKB1SLC22A3BLM
SCHEMBL11951618 0.80 ALDH1A1 (0.47) PPARGPPARDPPARACYP1A2CYP2C9
SCHEMBL15189280 0.79 TUBB4A (0.61) CYP3A4TSHRPPARGPPARDPPARA
SCHEMBL661285 0.79 PDE4D (0.46) CYP3A4TSHRPPARGPPARDPPARA
SCHEMBL24015482 0.78 CYP3A4 (0.50) CYP3A4TSHRPPARGPPARDPPARA
SCHEMBL12297021 0.78 CYP3A4 (0.50) CYP3A4TSHRPPARGPPARDPPARA
SCHEMBL29761292 0.77 TSHR (0.77) CYP3A4TSHRNPSR1NFKB1SLC22A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536157-B2 Non-steroidal compounds THE UNIVERSITY OF MELBOURNE (AU) 2013-09-17 US disclosed
US-8536157-B2 Non-steroidal compounds THE UNIVERSITY OF MELBOURNE (AU) 2013-09-17 US disclosed
US-20120046255-A1 NON-STEROIDAL COMPOUNDS THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) 2012-02-23 US disclosed
US-20120046255-A1 NON-STEROIDAL COMPOUNDS THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) 2012-02-23 US disclosed
WO-2008124878-A1 NON-STEROIDAL COMPOUNDS CRYPTOPHARMA PTY LTD (AU) 2008-10-23 WO disclosed
WO-2008124878-A1 NON-STEROIDAL COMPOUNDS CRYPTOPHARMA PTY LTD (AU) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046255-A1 NON-STEROIDAL COMPOUNDS PTGES2, PTGES, PTGES3 CYP3A4 500/4885TSHR 3564/4885PPARG 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.